OMass Therapeutics is an early stage drug discovery company specialized in applying state of the art biophysical platform technologies to discover therapies for severe unmet medical needs in immunology and genetically defined disorders. The company was founded by Professor Dame Carol Robinson to leverage her pioneering work in native mass spectrometry, in studies of dynamic protein assemblies, to characterise challenging drug targets including membrane proteins. The high resolution of our biophysical platform offers an unprecedented advantage in the detection of drug leads.

The company vision is to build an integrated drug discovery company, with biophysical platform technologies at its core, and develop a pipeline of novel therapies. Our ambition is to develop and ultimately commercialise our products.